The primary objectives of this study are to compare sacituzumab tirumotecan to Treatment of
Physician's Choice (TPC) with respect to progression-free survival (PFS) per response
evaluation criteria in solid tumors (RECIST 1.1), as assessed by blinded independent central
review (BICR), and overall survival (OS). The primary hypotheses are that sacituzumab
tirumotecan is superior to TPC with respect to PFS per RECIST 1.1, as assessed by BICR, and
that sacituzumab tirumotecan is superior to TPC with respect to OS.

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion Criteria:

- Has a histologically-confirmed diagnosis of endometrial carcinoma or carcinosarcoma.

- Has radiographically evaluable disease, either measurable or nonmeasurable per
response evaluation criteria in solid tumors (RECIST 1.1), as assessed by blinded
independent central review (BICR).

- Has received prior platinum-based chemotherapy and anti-programmed cell death 1
protein (PD-1)/anti- programmed cell death ligand 1 (PD-L1) therapy, either separately
or in combination.

Exclusion Criteria:

- Has neuroendocrine tumors or endometrial sarcoma, including stromal sarcoma,
leiomyosarcoma, adenosarcoma, or other types of pure sarcomas.

- Has a history of documented severe dry eye syndrome, severe Meibomian gland disease
and/or blepharitis, or corneal disease that prevents/delays corneal healing.

- Has active inflammatory bowel disease requiring immunosuppressive medication or
previous history of inflammatory bowel disease.

- Has had a recurrence of endometrial carcinoma or carcinosarcoma more than 180 days
after completing platinum-based therapy administered in the curative-intent or
adjuvant setting without any additional platinum-based therapy received in the
metastatic or recurrent setting.

- Has received more than 3 prior lines of therapy for endometrial carcinoma or
carcinosarcoma.

If you are interested in participating in this study, call The JamesLine at 800-293-5066 to make an appointment with the principal investigator listed or ask your doctor if you are eligible for this study.